Treatment of paroxysmal supraventricular tachycardia with adenosine

Implications for nursing

A. L. Severson, Linda Meyer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Paroxysmal supraventricular tachycardia (PSVT) is a frequently occurring arrhythmia. Currently, verapamil and manual vagal stimulation are the first- line interventions for PSVT. Although verapamil is widely used for the treatment of PSVT, it can result in hypotension and ventricular fibrillation if given to a patient with ventricular tachycardia. Because the differential diagnosis of broad QRS complex tachycardia is difficult, the development of a safer drug for the treatment of both narrow- and broad-complex tachycardia is extremely important. Adenosine is a promising new drug for the treatment of PSVT. Its use is reviewed in three presentations.

Original languageEnglish (US)
Pages (from-to)350-356
Number of pages7
JournalHeart and Lung: Journal of Critical Care
Volume21
Issue number4
StatePublished - 1992

Fingerprint

Paroxysmal Tachycardia
Supraventricular Tachycardia
Adenosine
Nursing
Verapamil
Tachycardia
Ventricular Fibrillation
Therapeutics
Ventricular Tachycardia
Pharmaceutical Preparations
Hypotension
Cardiac Arrhythmias
Differential Diagnosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Critical Care and Intensive Care Medicine
  • Pulmonary and Respiratory Medicine

Cite this

Treatment of paroxysmal supraventricular tachycardia with adenosine : Implications for nursing. / Severson, A. L.; Meyer, Linda.

In: Heart and Lung: Journal of Critical Care, Vol. 21, No. 4, 1992, p. 350-356.

Research output: Contribution to journalArticle

@article{f658a0c07f0245ad8cd9e13fb6415c92,
title = "Treatment of paroxysmal supraventricular tachycardia with adenosine: Implications for nursing",
abstract = "Paroxysmal supraventricular tachycardia (PSVT) is a frequently occurring arrhythmia. Currently, verapamil and manual vagal stimulation are the first- line interventions for PSVT. Although verapamil is widely used for the treatment of PSVT, it can result in hypotension and ventricular fibrillation if given to a patient with ventricular tachycardia. Because the differential diagnosis of broad QRS complex tachycardia is difficult, the development of a safer drug for the treatment of both narrow- and broad-complex tachycardia is extremely important. Adenosine is a promising new drug for the treatment of PSVT. Its use is reviewed in three presentations.",
author = "Severson, {A. L.} and Linda Meyer",
year = "1992",
language = "English (US)",
volume = "21",
pages = "350--356",
journal = "Heart and Lung: Journal of Acute and Critical Care",
issn = "0147-9563",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment of paroxysmal supraventricular tachycardia with adenosine

T2 - Implications for nursing

AU - Severson, A. L.

AU - Meyer, Linda

PY - 1992

Y1 - 1992

N2 - Paroxysmal supraventricular tachycardia (PSVT) is a frequently occurring arrhythmia. Currently, verapamil and manual vagal stimulation are the first- line interventions for PSVT. Although verapamil is widely used for the treatment of PSVT, it can result in hypotension and ventricular fibrillation if given to a patient with ventricular tachycardia. Because the differential diagnosis of broad QRS complex tachycardia is difficult, the development of a safer drug for the treatment of both narrow- and broad-complex tachycardia is extremely important. Adenosine is a promising new drug for the treatment of PSVT. Its use is reviewed in three presentations.

AB - Paroxysmal supraventricular tachycardia (PSVT) is a frequently occurring arrhythmia. Currently, verapamil and manual vagal stimulation are the first- line interventions for PSVT. Although verapamil is widely used for the treatment of PSVT, it can result in hypotension and ventricular fibrillation if given to a patient with ventricular tachycardia. Because the differential diagnosis of broad QRS complex tachycardia is difficult, the development of a safer drug for the treatment of both narrow- and broad-complex tachycardia is extremely important. Adenosine is a promising new drug for the treatment of PSVT. Its use is reviewed in three presentations.

UR - http://www.scopus.com/inward/record.url?scp=0026752084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026752084&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 350

EP - 356

JO - Heart and Lung: Journal of Acute and Critical Care

JF - Heart and Lung: Journal of Acute and Critical Care

SN - 0147-9563

IS - 4

ER -